Related Experiment Videos
Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study
1Einstein-Moss Center for Adults with Developmental Disabilities, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141.
Abstract:
Self-injury is common in mentally retarded persons and often unresponsive to pharmacotherapy. Based on the assumption that this maladaptive behavior may be related to central nervous system serotonergic imbalance or dysfunction, an open trial with a serotonin uptake inhibitor was conducted. Twenty-one severely to profoundly mentally retarded persons with aggression and self-injurious behavior were treated with 20-40 mg of fluoxetine daily. Marked improvement occurred in 13 patients, moderate in 4, mild in 2, and no improvement in 2 patients treated for a minimum of 3 months. Positive changes occurred in the areas of self-injury, agitation, emotional lability, and aggression. Only one patient required discontinuation of the medication because of anorexia and weight loss; all other patients tolerated the drug without any significant side effects. All were concurrently taking other psychotropic medications, and no adverse drug interactions were noted. Future trials will focus on more homogeneous patient samples and on the therapeutic interactions between concurrently administered psychotropic medications.
Insights
Fluoxetine, a serotonin uptake inhibitor, effectively reduced self-injury and aggression in individuals with intellectual disabilities. This study highlights fluoxetine as a potential treatment for maladaptive behaviors in this population.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Self-injury and aggression are prevalent in individuals with intellectual disabilities.
- These behaviors are often resistant to traditional pharmacotherapy.
- Potential link between serotonergic system dysfunction and maladaptive behaviors.
Purpose of the Study:
- To investigate the efficacy of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), in treating self-injurious and aggressive behaviors in individuals with intellectual disabilities.
- To assess the safety and tolerability of fluoxetine in this patient population.
Main Methods:
- An open-label trial involving 21 participants with severe to profound intellectual disabilities and co-occurring aggression and self-injurious behavior.
- Participants were treated with daily doses of fluoxetine ranging from 20-40 mg for a minimum of 3 months.
- Concurrent use of other psychotropic medications was permitted.
Main Results:
- Significant improvements in self-injury, agitation, emotional lability, and aggression were observed.
- Marked improvement in 13 patients, moderate in 4, mild in 2, and no improvement in 2 patients.
- Fluoxetine was generally well-tolerated, with only one patient discontinuing due to anorexia and weight loss.
- No significant adverse drug interactions were noted despite concurrent psychotropic medication use.
Conclusions:
- Fluoxetine demonstrates significant efficacy in reducing self-injurious and aggressive behaviors in individuals with intellectual disabilities.
- The medication is well-tolerated, suggesting a favorable safety profile for this population.
- Further research with homogeneous patient samples and investigation of drug interactions is warranted.